Anda belum login :: 27 Nov 2024 07:18 WIB
Detail
ArtikelLong-term treatment of uterine fibroids with ulipristal acetate  
Oleh: Donnez, Jacques ; Vazquez, Francisco ; Tomaszewski, Janusz ; Nouri, Kazem ; Bouchard, Philippe
Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 101 no. 06 (Jun. 2014), page 1565–1573.
Topik: Long-term treatment; ulipristal acetate; uterine fibroid
Ketersediaan
  • Perpustakaan FK
    • Nomor Panggil: F02.K.2014.02
    • Non-tandon: 1 (dapat dipinjam: 0)
    • Tandon: tidak ada
    Lihat Detail Induk
Isi artikelObjective To investigate the efficacy and safety of ulipristal acetate (UPA) for long-term treatment of symptomatic uterine fibroids. Design Repeated intermittent open-label UPA courses, each followed by randomized double-blind norethisterone acetate (NETA) or placebo. Setting European clinical gynecology centers. Patient(s) Two hundred and nine women with symptomatic fibroids including heavy menstrual bleeding. Intervention(s) Patients received up to four 3-month courses of UPA 10 mg daily, immediately followed by 10-day double-blind treatment with NETA (10 mg daily) or placebo. Main Outcome Measure(s) Amenorrhea, fibroid volume, endometrial histology. Result(s) After the first UPA course, amenorrhea occurred in 79% of women, with median onset (from treatment start) of 4 days (interquartile range, 2–6 days). Median fibroid volume change was -45% (interquartile range, -66%; -25%). Amenorrhea rates were 89%, 88%, and 90% for the 131, 119, and 107 women who received treatment courses 2, 3, and 4, respectively. Median times to amenorrhea were 2, 3, and 3 days for treatment courses 2, 3, and 4, respectively. Median fibroid volume changes from baseline were -63%, -67%, and -72% after treatment courses 2, 3, and 4, respectively. All endometrial biopsies showed benign histology without hyperplasia; NETA did not affect fibroid volume or endometrial histology. Conclusion(s) Repeated 3-month UPA courses effectively control bleeding and shrink fibroids in patients with symptomatic fibroids. Clinical trial registration ClinicalTrials.gov (www.clinicaltrials.gov) registration numbers NCT01156857 (PEARL III) and NCT01252069 (PEARL III extension).
Opini AndaKlik untuk menuliskan opini Anda tentang koleksi ini!

Kembali
design
 
Process time: 0.015625 second(s)